ASND supply chain intelligence for Ascendis Pharma A/S: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Ascendis Pharma A/S (ASND) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| NVO | Novo Nordisk A/S | 90% | Reciprocal relationship from NVO graph: Reciprocal relationship from ASND graph: Reciprocal relationship from NVO graph: Reciprocal relationship from ASND graph: we entered into a research and develo… |
| VISEN-PHARMACEUTICALS | VISEN-PHARMACEUTICALS | 90% | In connection with the formation of VISEN, we granted VISEN exclusive rights to develop and commercialize our rare disease endocrinology products based on our proprietary TransCon technologies |
| TEIJIN-LIMITED | TEIJIN-LIMITED | 85% | we entered into an exclusive license agreement with Teijin Limited, to develop and commercialize Tr |
| HOWL | Werewolf Therapeutics, Inc. | 72% | Reciprocal relationship from HOWL graph: Reciprocal relationship from ASND graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from ASND graph: Reciprocal relationship from HOWL g… |
| OPK | OPKO Health, Inc. | 72% | Reciprocal relationship from OPK graph: aboratories, molecular diagnostic firms, universities and research institutions. Most of these companies have substantially greater financial and other resourc… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| APAM | Artisan Partners Asset Management Inc. | 72% | er for the RA Fund and may be deemed a beneficial owner of ADSs held by the RA Fund. The RA Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities hel… |
| APAM | Artisan Partners Asset Management Inc. | 72% | Reciprocal relationship from APAM graph: Reciprocal relationship from ASND graph: Reciprocal relationship from APAM graph: Reciprocal relationship from ASND graph: er for the RA Fund and may be deeme… |
| HOWL | Werewolf Therapeutics, Inc. | 72% | Reciprocal relationship from HOWL graph: Reciprocal relationship from ASND graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from ASND graph: Reciprocal relationship from HOWL g… |
| JHG | Janus Henderson Group plc | 72% | Reciprocal relationship from JHG graph: Reciprocal relationship from ASND graph: rizes maturity analysis (on an undiscounted basis) for non-derivative financial liabilities recognized in the consolid… |
| JHG | Janus Henderson Group plc | 72% | rizes maturity analysis (on an undiscounted basis) for non-derivative financial liabilities recognized in the consolidated statements of financial position: (EUR’000) < 1 year 1-5 years >5 years Tota… |
| NKTR | Nektar Therapeutics | 72% | roduct containers and closures; production and process controls; packaging and labeling controls; holding and distribution; laboratory controls; records and reports; and returned or salvaged products… |
| NKTR | Nektar Therapeutics | 72% | Reciprocal relationship from NKTR graph: Reciprocal relationship from ASND graph: roduct containers and closures; production and process controls; packaging and labeling controls; holding and distrib… |
| NVO | Novo Nordisk A/S | 72% | Reciprocal relationship from NVO graph: Reciprocal relationship from ASND graph: established an integrated organization to commercialize the Company’s approved Endocrinology Rare Disease products, YO… |
| NVO | Novo Nordisk A/S | 72% | established an integrated organization to commercialize the Company’s approved Endocrinology Rare Disease products, YORVIPATH ® and SKYTROFA ® . In Europe, the Company has established its presence by… |
| OPK | OPKO Health, Inc. | 72% | Reciprocal relationship from OPK graph: Reciprocal relationship from ASND graph: roduct containers and closures; production and process controls; packaging and labeling controls; holding and distribu… |
| OPK | OPKO Health, Inc. | 72% | roduct containers and closures; production and process controls; packaging and labeling controls; holding and distribution; laboratory controls; records and reports; and returned or salvaged products… |
| SER | Serina Therapeutics, Inc. | 72% | roduct containers and closures; production and process controls; packaging and labeling controls; holding and distribution; laboratory controls; records and reports; and returned or salvaged products… |
| SER | Serina Therapeutics, Inc. | 72% | Reciprocal relationship from SER graph: Reciprocal relationship from ASND graph: Reciprocal relationship from SER graph: Reciprocal relationship from ASND graph: roduct containers and closures; produ… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from ASND graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ASND graph: Reciprocal relationship from SNYN… |
| SNYNF | Sanofi | 72% | LPs”), for certain nonclinical studies, and good clinical practices (“GCPs”), for clinical studies. GLPs and GCPs are regulations and guidelines enforced by the FDA and comparable foreign regulatory … |
| CARBOGEN-AMCIS-AG | CARBOGEN-AMCIS-AG | 62% | rly Medicom Innovation Partner A/S). The intermediates of our proprietary TransCon linkers are made by CARBOGEN AMCIS AG under an agreement with CARBOGEN AMCIS AG and accompanying purchase orders. Fo… |
| FUJIFILM-DIOSYNTH-BIOTECHNOLOGIES-UK-LIMITED | FUJIFILM-DIOSYNTH-BIOTECHNOLOGIES-UK-LIMITED | 62% | th Fujifilm Diosynth Biotechnologies UK Limited (“Fujifilm”), and Lonza Ltd. Our PTH as well as our TransCon PTH drug substance is supplied by Bachem, Switzerland, pursuant to our agreement with Bach… |
| NOF-CORPORATION | NOF-CORPORATION | 62% | rly Medicom Innovation Partner A/S). The intermediates of our proprietary TransCon linkers are made by CARBOGEN AMCIS AG under an agreement with CARBOGEN AMCIS AG and accompanying purchase orders. Fo… |
| YPSOMED-AG | YPSOMED-AG | 62% | ges and assembles the cartridges with a drug delivery device made by Ypsomed AG. CNP drug substance is supplied by Wacker Biotech, Germany. Our TransCon CNP drug product in vials is manufactured by V… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ASND-DEBT | Debt stack $1.0B | 90% | Market cache reports total debt of $1.0B. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ASND-OWNER-WELLINGTON-MANAGEMENT-GROUP-LLP | WELLINGTON MANAGEMENT GROUP LLP | 95% | 13F/ownership overlay lists WELLINGTON MANAGEMENT GROUP LLP; shares held 1,757,633; value $402.0B; as of 2026-03-31. |
| ASND-OWNER-PERCEPTIVE-ADVISORS-LLC | PERCEPTIVE ADVISORS LLC | 95% | 13F/ownership overlay lists PERCEPTIVE ADVISORS LLC; shares held 3,062,842; value $700.6B; as of 2026-03-31. |
| ASND-OWNER-RA-CAPITAL-MANAGEMENT-L-P | RA CAPITAL MANAGEMENT, L.P. | 95% | 13F/ownership overlay lists RA CAPITAL MANAGEMENT, L.P.; shares held 10,281,496; ownership 16.59%; value $2.35T; as of 2026-03-31. |
| ASND-OWNER-AVORO-CAPITAL-ADVISORS-LLC | Avoro Capital Advisors LLC | 95% | 13F/ownership overlay lists Avoro Capital Advisors LLC; shares held 10,223,611; value $2.25T; as of 2026-03-31. |
| ASND-OWNER-MASSACHUSETTS-FINANCIAL-SERVICES-CO-MA | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 95% | 13F/ownership overlay lists MASSACHUSETTS FINANCIAL SERVICES CO /MA/; shares held 1,860,669; value $425.6B; as of 2026-03-31. |
| ASND-OWNER-CAPITAL-INTERNATIONAL-INVESTORS | Capital International Investors | 95% | 13F/ownership overlay lists Capital International Investors; shares held 1,958,843; value $448.0B; as of 2026-03-31. |
| ASND-OWNER-FRANKLIN-RESOURCES-INC | FRANKLIN RESOURCES INC | 95% | 13F/ownership overlay lists FRANKLIN RESOURCES INC; shares held 2,051,948; value $469.3B; as of 2026-03-31. |
| ASND-OWNER-WESTFIELD-CAPITAL-MANAGEMENT-CO-LP | WESTFIELD CAPITAL MANAGEMENT CO LP | 95% | 13F/ownership overlay lists WESTFIELD CAPITAL MANAGEMENT CO LP; shares held 4,813,440; value $1.10T; as of 2026-03-31. |
| ASND-OWNER-FMR-LLC | FMR LLC | 95% | 13F/ownership overlay lists FMR LLC; shares held 3,876,601; value $886.7B; as of 2026-03-31. |
| ASND-OWNER-ARTISAN-PARTNERS-LIMITED-PARTNERSHIP | Artisan Partners Limited Partnership | 95% | 13F/ownership overlay lists Artisan Partners Limited Partnership; shares held 3,230,188; value $738.8B; as of 2026-03-31. |
| ASND | Ascendis Pharma A/S | 82% | HOLTUG LARS | sell | 236 shares |
| ASND | Ascendis Pharma A/S | 82% | BIENAIME JEAN JACQUES | grant | 9160 shares |
| ASND | Ascendis Pharma A/S | 82% | Bodenhoff Mads | option_exercise | 3000 shares |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CALC | CalciMedica, Inc. | 100.00 | 2 | |
| NVO | Novo Nordisk A/S | 100.00 | 1 | ['customer', 'supplier'] |
| CUE | Cue Biopharma, Inc. | 100.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| CANF | Can-Fite BioPharma Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 |